TL;DR
This study identifies two novel polyketide compounds, asperulosins A and B, from the fungus Aspergillus rugulosa, demonstrating significant anti-inflammatory properties. These compounds, particularly asperulosin A, show promise as potential therapeutic agents by effectively suppressing key inflammatory pathways, including nitric oxide production and the activation of NF-κB.
What Problem Does This Paper Address?
Inflammation is a critical biological process, but its dysregulation is implicated in numerous chronic diseases. While many anti-inflammatory drugs exist, there's a continuous need for novel compounds with improved efficacy and fewer side effects. Natural products, particularly those derived from fungi, have historically been a rich source of bioactive molecules. This paper addresses the challenge of discovering new anti-inflammatory agents by exploring the chemical diversity of the fungus Aspergillus rugulosa, a source not extensively studied for its secondary metabolites with anti-inflammatory potential.
Methods
The researchers employed a multi-faceted approach:
- Isolation and Structure Elucidation: Standard chromatographic techniques (silica gel column chromatography, Sephadex LH-20, and semi-preparative HPLC) were used to isolate compounds from the fungal extract. Structural characterization was achieved through high-resolution electrospray ionization mass spectrometry (HRESIMS) and comprehensive 1D and 2D Nuclear Magnetic Resonance (NMR) spectroscopy.
- Absolute Configuration Determination: For new compounds, the absolute configurations were determined by comparing experimental Electronic Circular Dichroism (ECD) spectra with calculated ECD spectra using the TDDFT method.
- Anti-inflammatory Assays:
- Nitric Oxide (NO) Production: RAW264.7 macrophage cells were stimulated with lipopolysaccharide (LPS) to induce inflammation. The production of NO was measured using the Griess reagent.
- Cytokine Profiling: The secretion levels of various pro-inflammatory (IL6, TNF-α, IFN-γ, MCP-1, IL12) and anti-inflammatory (IL10) cytokines were assessed using a Cytometric Bead Array (CBA) kit.
- Gene Expression Analysis: Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) was used to measure the transcription levels of inflammatory markers (IL6, IL1β, TNF-α) and M2 macrophage markers (ARG1, CD206).
- Protein Expression and Localization: Western blotting was employed to analyze the protein levels of key inflammatory mediators like iNOS, COX-2, and NF-κB p65. Immunofluorescence microscopy was used to visualize the nuclear translocation of NF-κB p65.
- Molecular Docking: Computational docking studies were performed to predict the binding interactions of compounds 1 and 5 with the NF-κB p65 protein, providing insights into their mechanism of action.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Novel Polyketide Structures: The discovery of asperulosins A and B (compounds 1 and 2) adds to the known chemical diversity of polyketides, with compound 2 featuring a rare five-continuous quaternary carbon atom structure.
- Potent Anti-inflammatory Activity: Compounds 1 and 5 demonstrated significant inhibition of LPS-induced NO production in macrophages, with IC50 values comparable to or better than the positive control, dexamethasone.
- Modulation of Cytokine Balance: Both compounds effectively shifted the cytokine profile from pro-inflammatory (IL6, TNF-α, IFN-γ, MCP-1, IL12) towards anti-inflammatory (IL10), indicating a broad impact on the immune response.
- Inhibition of M1 Macrophage Polarization: The compounds suppressed key M1 macrophage markers at both the transcriptional and protein levels, while simultaneously upregulating M2 macrophage markers, suggesting a role in rebalancing immune cell phenotypes.
- NF-κB Pathway Inhibition: A crucial finding is the ability of compounds 1 and 5 to inhibit the activation and nuclear translocation of NF-κB, a master regulator of inflammation, and its downstream targets like iNOS and COX-2.
- Mechanism of Action Insights: Molecular docking suggests that compound 1 has a stronger binding affinity to NF-κB p65 than compound 5, potentially explaining its superior anti-inflammatory effects.
Key Results
- Isolation: Two new polyketides (asperulosins A and B, 1-2) and one new prenylated small molecule (asperulosin C, 3) were isolated, along with nine known compounds (4-12).
- NO Inhibition: Compound 1 showed an IC50 of 1.49 ± 0.31 µM, and compound 5 showed an IC50 of 3.41 ± 0.85 µM for NO production inhibition. Other compounds had IC50 values >40 µM.
- Cytokine Modulation: Compounds 1 and 5 significantly increased IL10 levels and decreased IL6, TNF-α, IFN-γ, MCP-1, and IL12 levels in LPS-stimulated RAW264.7 cells.
- Gene Expression: Compounds 1 and 5 inhibited the mRNA expression of IL6, IL1β, and TNF-α, while increasing IL10, ARG1, and CD206 mRNA.
- Protein Expression: Compounds 1 and 5 inhibited iNOS and COX-2 mRNA and protein expression. Compound 1 showed more potent inhibition of TLR4, iNOS, and NF-κB p65 protein expression compared to compound 5.
- NF-κB Translocation: Immunofluorescence confirmed that compounds 1 and 5 inhibited the nuclear translocation of NF-κB p65.
Limitations and Future Work
- In Vitro Focus: The study primarily focused on in vitro assays using cell lines. Further in vivo studies are needed to confirm the efficacy and safety of these compounds in animal models.
- Mechanism Elucidation: While NF-κB inhibition is a key finding, a more comprehensive understanding of the precise molecular targets and downstream signaling cascades affected by these compounds could be explored.
- Structure-Activity Relationship (SAR): Further SAR studies could be conducted to optimize the anti-inflammatory activity of these compounds and develop more potent analogs.
- Synthesis: The paper mentions that compound 1 is a unique linear chain compound. Exploring synthetic routes to these compounds could facilitate large-scale production and further derivatization for drug development.
- Comparative Activity: While the compounds were compared to dexamethasone, a more extensive panel of positive controls and a wider range of inflammatory conditions could provide a more robust comparison.
Summary updated